AnPac Bio-Medical jumps on immunology testing contract

Fresh2

15/09/2020 14:11

** Chinese biotech co's U.S. shares  ANPC.O  rise ~15% to
5.37% premarket
    ** ANPC says it secured a 14-mth sales contract with Chinese
health management firm Beijing Yuan Jian Health Management Co
Ltd for its new immunology test, AnPac Defense Medical
Examination (ADME)  urn:newsml:reuters.com:*:nGNXMv7Q7
    ** Contract includes 20,000 paid ADME tests, with
expectation of offering to end customers at multiple locations
in China 
    ** The new immunology test is based on the learning and
intellectual property of co's cancer differentiation analysis
technology (CDA), which measures bio-physical signals in the
blood
    ** ANPC in June signed a $3 mln cancer-screening contract
with Beijing Yuan Jian and in Sept. reported positive data from
a cancer monitoring tech study  urn:newsml:reuters.com:*:nL4N2DW30N  urn:newsml:reuters.com:*:nL4N2G12I4
    ** ANPC has two certified clinical labs in China and one in
the U.S., where it performs a suite of cancer screening and
detection tests
    ** More than 215,210 shares trade before open, 77.3x their
25-day moving avg
    ** Stock down 58.5% YTD since Jan. 30 IPO

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))